Article
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Clinical colorectal cancer - 1 Sept 2011
Cohn Allen L, Shumaker Grace C, Khandelwal Pankaj, Smith David A, Neubauer Marcus A, Mehta Nilesh, Richards Donald, Watkins David L, Zhang Kathy, Yassine Mohamed R
Abstract excerpt
BACKGROUND: This prospective analysis evaluated the effect of tumor KRAS status on efficacy of second-line panitumumab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI). METHODS: This phase 2, open-label, single-arm study enrolled patients with unresectable, measurable metastatic colorectal cancer (mCRC) after failure of first-line treatment with oxaliplatin-based chemotherapy plus bevacizumab. Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.